Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

May 31, 2017

Conditions
Recurrent Follicular Lymphoma
Interventions
DRUG

idelalisib

oral

DRUG

lenalidomide

oral

Trial Locations (6)

10065

Weill Medical College of Cornell University, New York

20007

MedStar Georgetown University Hospital, Washington D.C.

27599

University of North Carolina at Chapel Hill, Chapel Hill

43210

Ohio State University Medical Center, Columbus

60637

University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Gilead Sciences

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

Alliance for Clinical Trials in Oncology

OTHER